Thermo Fisher to acquire Brammer Bio

With so much growth in the area of gene therapies, Thermo Fisher Scientific, an american biotechnology product development company, has decided to buy Brammer Bio, a contract development and manufacturing organization (CDMO) focusing on manufacturing viral vectors for gene and cell therapies.

The $1.7 billion cash deal should close at the end of the second quarter of 2019. Thermo Fisher will gain , manufacturing locations in Massachusetts and Florida, along with around 600 employees.

Click here to read the entire article.